Back to search results

Tiprelestat for Pulmonary Arterial Hypertension (PAH)

This study is testing a drug called Tiprelestat, given as a daily shot, for people with Pulmonary Arterial Hypertension (PAH). You would receive either Tiprelestat (5 mg or 10 mg) or a placebo (an inactive shot) in addition to your usual care. Researchers want to see if Tiprelestat can improve your Pulmonary Vascular Resistance (PVR), which is a measure of blood pressure in the lungs. This study is for adults aged 18 to 75 who have been diagnosed with WHO Group I PAH and are experiencing symptoms despite current treatments. The study aims to enroll 90 participants.

Study design
This is an interventional study comparing Tiprelestat to a placebo, with 90 planned participants. The phase of the study is not specified.
What's involved
Participants would receive a daily subcutaneous injection for 168 days. The primary endpoint, change in PVR, is measured from the start of the study to week 24.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at week 24, which is after the 168 days of treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07601295

Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)

Not Yet Recruiting
PHASE2Ages 18–75InterventionalTreatment
Stanford University
~90 participants
Updated 2026-05-22 on ClinicalTrials.gov
What's tested:Tiprelestat (5 mg)Placebo (1 mL 0.9% saline solution)Tiprelestat (10 mg)

At a glance

Recruiting sites
0 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Pulmonary Vascular Resistance (PVR)
Measured over Baseline to week 24

Conditions

Pulmonary Arterial Hypertension (PAH)

Explore related trials

Pulmonary Arterial HypertensionElafin

NCT07601295

Where you'd take part

This study runs at 10 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Brown University/Rhode Island Hospital

    Providence, Rhode Islandno site contact published

  • Duke University

    Durham, North Carolinano site contact published

  • Harvard University / Brigham and Women's Hospital

    Boston, Massachusettsno site contact published

  • Stanford University

    Stanford, Californiano site contact published

  • The University of Arizona / Banner University Medical Center

    Tucson, Arizonano site contact published

  • University of California, San Francisco

    San Francisco, Californiano site contact published

  • University of Colorado (UCD) Anschutz

    Aurora, Coloradono site contact published

  • University of Pennsylvania

    Philadelphia, Pennsylvaniano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Roham T Zamanian, MD · PRINCIPAL_INVESTIGATOR · Stanford University

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Change in Pulmonary Vascular Resistance (PVR)Baseline to week 24

    PVR is calculated based on direct measurements during the right heart catheterization (RHC) procedure. PVR = (mPAP - PAWP) / CO, where mPAP is the mean pulmonary artery pressure, PAWP is the pulmonary wedge arterial pressure, and CO is the cardiac output. These cardiac measures are also obtained from right heart catheterization. PVR is measured in Wood units (WU) or dynes (dynes\*sec/cm5), and higher values are associated with more severe disease. Normal range for PVR is 1-3 WU (80-240 dynes\*sec/cm5) and can be as high as 30 WU (2,400 80-240 dynes\*sec/cm5) in disease.